News

Researchers identify way to grow immune cells at large scale for preventing cancer reoccurrence

For the first time, Mount Sinai researchers have identified a way to make large numbers of immune cells that can help prevent cancer reoccurrence, according to a study published in August in Cell Reports. The researchers discovered a way to grow the immune cells, called dendritic cells, at large scale in the lab to study them … Continued

Read More

‘Hijacked’ cell response to stress reveals promising drug targets for blood cancer

A signaling pathway that helps promote normal cell growth worsens a form of leukemia by taking control of another pathway better known for protecting cells from biological stress, a new study shows. The discovery that the NOTCH1 pathway takes control of heat shock transcription factor 1 (HSF1) signaling in T cell acute lymphoblastic leukemia, or … Continued

Read More

CSHL’s Camila dos Santos scores family’s second $600K award

TBR News Media They aren’t quite wonder twins, but some day the dedicated work of husband and wife scientists Christopher Vakoc and Camila dos Santos may help people batting against a range of cancers, from leukemia to breast cancer. Dos Santos and Vakoc are the first family of prize winners in the Pershing Square Foundation’s … Continued

Read More

SBU’s Benjamin Martin scores first Sohn Research Prize

TBR News Media Up and coming scientists are often stuck in the same position as promising professionals in other fields. To get the funding for research they’d like to do, they need to show results, but to get results, they need funding. Joseph Heller, author of “Catch 22,” would certainly relate. A New York-based philanthropy … Continued

Read More

Study reveals a way to make prostate cancer cells run out of energy and die

Cold Spring Harbor, NY – Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered that cells lacking the tumor-suppressor protein PTEN–a feature of many cancers– are particularly vulnerable to drugs that impair their energy-producing mitochondria. Such drugs induce them to literally eat themselves to death, the research shows. Unlike normal cells, cells without PTEN seem … Continued

Read More

Quentis Therapeutics Debuts with $48 Million Series A Financing to Advance First-in-Class Immunotherapies Targeting Endoplasmic Reticulum Stress Response Pathways

–Versant-seeded company focused on applying novel biology to boost anti-tumor immunity– —Foundational science stems from landmark ER stress biology research at Weill Cornell Medicine— —Michael Aberman, M.D., former SVP of Strategy for Regeneron, appointed as President and Chief Executive Officer— NEW YORK–(BUSINESS WIRE)–Quentis Therapeutics Inc., a biotechnology company pursuing next-generation immuno-oncology research and drug development, … Continued

Read More

New immunotherapy approach boosts body’s ability to destroy cancer cells

Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes after infectious microorganisms. Yet these treatments only benefit some patients, and remain ineffective in the vast majority of cases. … Continued

Read More

Throwing molecular wrench into gene control machine leads to ‘melting away’ of leukemia

PUBLIC RELEASE: 8-JAN-2018 Cold Spring Harbor, NY – Cancer researchers today announced they have developed a way of sidelining one of the most dangerous “bad actors” in leukemia. Their approach depends on throwing a molecular wrench into the gears of an important machine that sets genes into motion, enabling cancer cells to proliferate. In tests in … Continued

Read More

Cancer’s Invasion Equation

We can detect tumors earlier than ever before. Can we predict whether they’re going to be dangerous? We’ve tended to focus on the cancer, but its host tissue—“soil,” rather than “seed”—could help us predict the danger it poses. Over the summer of 2011, the water in Lake Michigan turned crystal clear. Shafts of angled light lit … Continued

Read More

Celgene-backed cancer biotech Repare emerges from stealth with $68M

After 18 months being incubated by Versant Ventures, upstart Repare Therapeutics has emerged from stealth mode with an impressive $68 million, backing from Celgene and some big-name execs. The Montreal and Cambridge, Massachusetts, biotech saw founding investor Versant Ventures co-lead the series A round with MPM Capital. They were also joined by other syndicate investors … Continued

Read More